Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961204 · ClinicalTrials.gov registry record · Phase 4
Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
A Phase 4 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 662
- Enrollment target
NCT03961204 is a Phase 4 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 662 participants.
The verdict
NCT03961204, a Phase 4 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 662 participants
- Enrollment target
Study Summary
The objective of this study was to collect data both retrospectively and prospectively in order to evaluate the long-term outcomes, durability of effect, and real-world treatment patterns following treatment with Cladribine Tablets or placebo in participants with multiple sclerosis (MS) who were previously participated in the parent studies (ORACLE MS and CLARITY/CLARITY-EXT).
Interventions
- OTHER Data Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2021-05-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03961204
The ClinicalTrials.gov registry entry for NCT03961204 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 662 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Data Collection is the first listed.
NCT03961204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03961204 about?
NCT03961204 is a clinical study titled "Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)". The objective of this study was to collect data both retrospectively and prospectively in order to evaluate the long-term outcomes, durability of effect, and real-world treatment patterns following treatment with Cladribine Tablets or placebo in participants with multiple sclerosis (MS) who were pre...
What is the current status of trial NCT03961204?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 662 participants. The study started on 2019-08-15. Estimated completion is 2021-05-13.
What interventions are being tested in trial NCT03961204?
The interventions under investigation include: Data Collection (OTHER).
Who is sponsoring clinical trial NCT03961204?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.